Expertise in
10
conditions

Dr. Mark C. Walters

Pediatric Hematology Oncology
747 52nd Street, 
Oakland, CA 
Clinical Trials:Currently Recruiting for 1 Trial
37 Years of Experience
Expertise in
10
conditions
747 52nd Street, 
Oakland, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Walters is a Pediatric Hematologist Oncology provider in Oakland, California. Dr. Walters has been practicing medicine for over 37 years and is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Hemoglobinopathy, Congenital Hemolytic Anemia, Sickle Cell Disease, Hemolytic Anemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

747 52nd Street, Oakland, CA 94609

Additional Areas of Focus

Dr. Walters has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Enrollment Status: Recruiting
Publish Date: September 20, 2024
Intervention Type: Drug
Study Drug: CRISPR_SCD001
Study Phase: Phase 1/Phase 2
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Genetic
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Enrollment Status: Completed
Publish Date: December 14, 2023
Intervention Type: Genetic
Study Drug: BCL11A-Positive CD34-Positive Hematopoietic Stem Cells
Study Phase: Phase 1/Phase 2
Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
Enrollment Status: Terminated
Publish Date: June 26, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

74 Total Publications

Synthesis errors in oligonucleotides are propagated into the genome by homology-directed repair.
Synthesis errors in oligonucleotides are propagated into the genome by homology-directed repair.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2025
Similar Doctors
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Clara Lo
Pediatric Hematology Oncology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Clara Lo
Pediatric Hematology Oncology
725 Welch Rd, 
Palo Alto, CA 
 (28.1 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Clara Lo is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Lo is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Hemophilia A, Hemophilic Arthropathy, and Hereditary Spherocytosis.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Megan Gilbert
Pediatric Hematology Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Megan Gilbert
Pediatric Hematology Oncology

Lpch Medical Group Div Of Lucile

725 Welch Rd, 
Palo Alto, CA 
 (28.1 miles away)
650-498-7200
Languages Spoken:
English
See accepted insurances

Megan Gilbert is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Gilbert is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Hereditary Spherocytosis, Evans Syndrome, Congenital Hemolytic Anemia, and Splenectomy.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Michael Jeng
Pediatric Hematology Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Michael Jeng
Pediatric Hematology Oncology
725 Welch Rd, 
Palo Alto, CA 
 (28.1 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Michael Jeng is a Pediatric Hematologist Oncology provider in Palo Alto, California. Dr. Jeng is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Non-Langerhans-Cell Histiocytosis, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walters's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile